Cargando…
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study
BACKGROUND: Rhythm control for atrial fibrillation (AF) is cumbersome because of its progressive nature caused by structural remodelling. Upstream therapy refers to therapeutic interventions aiming to modify the atrial substrate, leading to prevention of AF. OBJECTIVE: The Routine versus Aggressive...
Autores principales: | Alings, M., Smit, M. D., Moes, M. L., Crijns, H. J. G. M., Tijssen, J. G. P., Brügemann, J., Hillege, H. L., Lane, D. A., Lip, G. Y. H., Smeets, J. R. L. M., Tieleman, R. G., Tukkie, R., Willems, F. F., Vermond, R. A., Van Veldhuisen, D. J., Van Gelder, I. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722377/ https://www.ncbi.nlm.nih.gov/pubmed/23700039 http://dx.doi.org/10.1007/s12471-013-0428-5 |
Ejemplares similares
-
Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
por: Nguyen, Bao Oanh, et al.
Publicado: (2021) -
Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study
por: Al-Jazairi, Meelad I H, et al.
Publicado: (2021) -
Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial
por: Zannad, Faiez, et al.
Publicado: (2015) -
Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial
por: Koldenhof, T, et al.
Publicado: (2023) -
Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
por: te Rijdt, W. P., et al.
Publicado: (2021)